title: [Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
abstract: OBJECTIVE
  To assess the in vitro susceptibilities of ocular bacterial isolates to Gatifloxacin and other fluoroquinolones which are often used in ophthalmic treatment.
  
  
  METHODS
  Non-randomized, non-comparative, retrospective study. Ocular bacterial isolates (n = 619) from Beijing Institute of Ophthalmology were tested for their susceptibilities to gatifloxacin, ciprofloxacin, ofloxacin and levofloxacin in vitro by the Kirby-Bauer disk diffusion method.
  
  
  RESULTS
  The total number of ocular bacterial isolates was 619 from January, 2005 to December, 2006 including gram-positive cocci 372(60.1%), gram-negative cocci 7 (1.1%), gram-positive bacilli 60 (9.7%), gram-negative bacilli 177 (28.6%), other 3 (0.5%). The percentage of susceptibility in total ocular bacterial isolates to gatifloxacin, ciprofloxacin, ofloxacin and levofloxacin was 88.4%, 72.1%, 64.8% and 54.4%. The susceptibility of Staphylococcus species to gatifloxacin (89.9%) was significantly higher than ciprofloxacin (38.8%), ofloxacin (48.2%) and levofloxacin (61.6%). Streptococcus species showed significantly higher susceptibility to gatifloxacin (93.2%), levofloxacin (89.2%) and ofloxacin (87.8%) than ciprofloxacin (62.2%). The susceptibility of gram-positive bacilli to gatifloxacin (86.7%) was significantly higher than ciprofloxacin (58.3%); All above differences are significant (P < 0.0083). Gram-negative cocci, enteric bacilli family and Pseudomonas species have the equivalent susceptibility to gatifloxacin, ciprofloxacin, ofloxacin and levofloxacin (P > 0.05).
  
  
  CONCLUSIONS
  Most of ocular bacterial are susceptible to gatifloxacin in vitro, especially gram-positive bacteria including Staphylococcus species, Streptococcus species and gram-positive bacilli.
authors.affiliation: Beijing Institute of Ophthalmology, Beijing Tongren Ophthalmic Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
authors.forename: Zhi-Qun
authors.initials: ZQ
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Ran
authors.initials: R
authors.lastname: Li
authors.forename: Shi-Yun
authors.initials: SY
authors.lastname: Luo
authors.forename: Xue-Qing
authors.initials: XQ
authors.lastname: Bai
authors.forename: Qing-Feng
authors.initials: QF
authors.lastname: Liang
authors.forename: Shi-Jing
authors.initials: SJ
authors.lastname: Deng
authors.forename: Xu-Guang
authors.initials: XG
authors.lastname: Sun
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002939:Ciprofloxacin / Q000494:pharmacology; D005123:Eye / Q000382:microbiology*; D024841:Fluoroquinolones / Q000494:pharmacology*; D000077734:Gatifloxacin; D006801:Humans; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D002939:Ciprofloxacin; D064704:Levofloxacin; D015242:Ofloxacin; D000077734:Gatifloxacin